bullish

Pharmaessentia Corp (6446 TT): Riding High Aided by Continued Strong Uptake of Besremi in US

332 Views14 Nov 2022 16:30
SUMMARY
  • Pharmaessentia Corp (6446 TT) reported revenue of NT$275 million for October, representing a massive 548% y/y growth. The year-to-date consolidated revenue totaled NT$2.3 billion, an increase of 628% y/y.
  • The company will be presenting new data on Besremi during the 64th American Society of Hematology (ASH) Annual Meeting to be held on December 10–13, 2022.
  • Pharmaessentia has been added to MSCI Taiwan Indexes. The company also gained the biggest weighting increase of 0.37 percentage points in the MSCI Taiwan Index.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
x